Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

NEW YORK, Feb. 8, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0769441/Ankylosing-Spondylitis-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Ankylosing Spondylitis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Ankylosing Spondylitis Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Ankylosing Spondylitis Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Ankylosing Spondylitis Therapeutics market

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Ankylosing Spondylitis Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Ankylosing Spondylitis Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Ankylosing Spondylitis Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Ankylosing Spondylitis Therapeutics - Introduction 72.1 Disease Overview 72.2 Epidemiology 72.2.1 Prevalence 72.2.2 Ethnicity 82.2.3 Gender 82.2.4 Quality of Life Parameters 92.2.5 Socioeconomic Impact 92.2.6 Mortality and Morbidity 92.3 Etiology and Pathology 92.4 Signs and Symptoms 102.5 Diagnosis 102.5.1 Patient History 102.5.2 Physical Examination 102.5.3 Laboratory Tests 112.5.4 Imaging Tests 112.5.5 Modified New York Criteria 122.6 Treatment and Management Options 122.6.1 Medications 122.6.2 Exercise and Physiotherapy 152.6.3 Surgery 152.7 Referral Pathway 152.8 GlobalData Pipeline Report Guidance 163 Ankylosing Spondylitis Therapeutics - Market Characterization 173.1 Overview 173.2 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Global 173.3 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Global 183.4 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - The US 193.5 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - The US 203.6 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - France 213.7 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - France 223.8 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Germany 233.9 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Germany 243.10 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Italy 253.11 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Italy 263.12 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Spain 273.13 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Spain 283.14 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - The UK 293.15 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - The UK 303.16 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Japan 313.17 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Japan 323.18 Drivers and Barriers for the Ankylosing Spondylitis Therapeutics Market 333.18.1 Drivers for the Ankylosing Spondylitis Therapeutics Market 333.18.2 Barriers for the Ankylosing Spondylitis Therapeutics Market 333.19 Opportunity and Unmet Need Analysis 343.20 Key Takeaway 344 Ankylosing Spondylitis Therapeutics - Competitive Assessment 354.1 Overview 354.2 Strategic Competitor Assessment 354.3 Product Profiles for the Major Marketed Products in the Ankylosing Spondylitis Market 364.3.1 Celebrex (celecoxib) 364.3.2 Arcoxia (etoricoxib) 374.3.3 Enbrel (etanercept) 384.3.4 Humira (adalimumab) 394.3.5 Remicade (infliximab) 414.3.6 Simponi (golimumab) 434.4 Key Takeaway 455 Ankylosing Spondylitis Therapeutics - Pipeline Assessment 465.1 Overview 465.2 Strategic Pipeline Assessment 465.3 Ankylosing Spondylitis Therapeutics Pipeline - Pipeline by Phases of Development 465.3.1 Ankylosing Spondylitis Therapeutics - Phase III Pipeline 475.3.2 Ankylosing Spondylitis Therapeutics - Phase II Pipeline 475.3.3 Ankylosing Spondylitis Therapeutics - Phase I Pipeline 475.3.4 Ankylosing Spondylitis Market - Pre-Clinical Pipeline 485.4 Ankylosing Spondylitis Therapeutics Market - Pipeline by Mechanism of Action 485.5 Technology Trends Analytic Framework 495.6 Ankylosing Spondylitis Therapeutics - Promising Drugs Under Development 505.7 Molecule Profile for Promising Drugs under Development 505.7.1 AIN457 (secukinumab) 505.7.2 Cimzia (certolizumab pegol) 515.8 Key Takeaway 516 Ankylosing Spondylitis Therapeutics - Clinical Trials Mapping 526.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 526.2 Clinical Trials by Phase 536.3 Clinical Trials by Trial Status 546.4 Prominent Sponsors 556.5 Top Companies Participating in Ankylosing Spondylitis Therapeutics Clinical Trials 577 Ankylosing Spondylitis Therapeutics - Strategic Assessment 587.1 Key Events Impacting the Future Market 587.2 Ankylosing Spondylitis Therapeutics: Implications for Future Market Competition 598 Ankylosing Spondylitis Therapeutics - Future Players 608.1 Introduction 608.2 Company Profiles 608.2.1 Novartis 608.2.2 UCB 639 Licensing and Partnership Deals 6410 Ankylosing Spondylitis Therapeutics - Appendix 6510.1 Market Definitions 6510.2 Abbreviations 6510.3 Methodology 6610.3.1 Coverage 6610.3.2 Secondary Research 6710.3.3 Forecasting 6710.3.4 Primary Research 6910.3.5 Expert Panel Validation 7010.4 Contact Us 7010.5 Disclaimer 7010.6 Bibliography 70

List of Tables

Table 1: Prevalence of Ankylosing Spondylitis in Different Ethnic Groups and Regions 8Table 2: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2006-2011 17Table 3: Ankylosing Spondylitis Therapeutics Market, Global, Forecast ($m), 2011-2019 18Table 4: Ankylosing Spondylitis Therapeutics Market, The US, Revenue ($m), 2006-2011 19Table 5: Ankylosing Spondylitis Therapeutics Market, The US, Forecast ($m), 2011-2019 20Table 6: Ankylosing Spondylitis Therapeutics Market, France, Revenue ($m), 2006-2011 21Table 7: Ankylosing Spondylitis Therapeutics Market, France, Forecast ($m), 2011-2019 22Table 8: Ankylosing Spondylitis Therapeutics Market, Germany, Revenue ($m), 2006-2011 23Table 9: Ankylosing Spondylitis Therapeutics Market, Germany, Forecast ($m), 2011-2019 24Table 10: Ankylosing Spondylitis Therapeutics Market, Italy, Revenue ($m), 2006-2011 25Table 11: Ankylosing Spondylitis Therapeutics Market, Italy, Forecast ($m), 2011-2019 26Table 12: Ankylosing Spondylitis Therapeutics Market, Spain, Revenue ($m), 2006-2011 27Table 13: Ankylosing Spondylitis Therapeutics Market, Spain, Forecast ($m), 2011-2019 28Table 14: Ankylosing Spondylitis Therapeutics Market, The UK, Revenue ($m), 2006-2011 29Table 15: Ankylosing Spondylitis Therapeutics Market, The UK, Forecast ($m), 2011-2019 30Table 16: Ankylosing Spondylitis Therapeutics Market, Japan, Revenue ($m), 2006-2011 31Table 17: Ankylosing Spondylitis Therapeutics Market, Japan, Forecast ($m), 2011-2019 32Table 18: Components of Ankylosing Spondylitis Disease Activity 38Table 19: Components of Ankylosing Spondylitis Disease Activity 40Table 20: Components of Ankylosing Spondylitis Disease Activity 42Table 21: Proportion of ASAS Responders at Weeks 14 and 24 43Table 22: Median Percent Improvement in ASAS Components AT Week 14 44Table 23: Ankylosing Spondylitis Therapeutics, Phase III Pipeline, 2011 47Table 24: Ankylosing Spondylitis Therapeutics, Phase II Pipeline, 2011 47Table 25: Ankylosing Spondylitis Therapeutics, Phase I Pipeline, 2011 47Table 26: Ankylosing Spondylitis Therapeutics, Pre-Clinical Pipeline, 2011 48Table 27: Ankylosing Spondylitis Therapeutics - Most Promising Drugs Under Development, 2011 50Table 28: Ankylosing Spondylitis Therapeutics, Clinical Trials by Country, 2011 52Table 29: Ankylosing Spondylitis Therapeutics, Clinical Trials by Phase, 2011 53Table 30: Ankylosing Spondylitis Therapeutics, Clinical Trials by Status of Development, 2011 54Table 31: Ankylosing Spondylitis Therapeutics, Prominent Sponsors, 2011 56Table 32: Ankylosing Spondylitis Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 57Table 33: Novartis - Inflammation and Immunology Pipeline, 2011 62Table 34: Novartis - Ankylosing Spondylitis Pipeline, 2011 62Table 35: UCB - Immunology Pipeline, 2011 63Table 36: UCB- Ankylosing Spondylitis Pipeline, 2011 63Table 37: Ankylosing Spondylitis Therapeutics, Global, Deals, 2009-2011 64

List of Figures

Figure 1: Ankylosing Spondylitis 7Figure 2: Pathogenesis of Ankylosing Spondylitis 10Figure 3: Modified New York Criteria 12Figure 4: Comparisons of NSAIDs 13Figure 5: Comparisons of DMARDs 13Figure 6: Comparisons of Corticosteroids 14Figure 7: Comparisons of Biologics 14Figure 8: Ankylosing Spondylitis Therapeutics - Referral Pathway 15Figure 9: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2006-2011 17Figure 10: Ankylosing Spondylitis Therapeutics Market, Global, Forecast ($m), 2011-2019 18Figure 11: Ankylosing Spondylitis Therapeutics Market, The US, Revenue ($m), 2006-2011 19Figure 12: Ankylosing Spondylitis Therapeutics Market, The US, Forecast ($m), 2011-2019 20Figure 13: Ankylosing Spondylitis Therapeutics Market, France, Revenue ($m), 2006-2011 21Figure 14: Ankylosing Spondylitis Therapeutics Market, France, Forecast ($m), 2011-2019 22Figure 15: Ankylosing Spondylitis Therapeutics Market, Germany, Revenue ($m), 2006-2011 23Figure 16: Ankylosing Spondylitis Therapeutics Market, Germany, Forecast ($m), 2011-2019 24Figure 17: Ankylosing Spondylitis Therapeutics Market, Italy, Revenue ($m), 2006-2011 25Figure 18: Ankylosing Spondylitis Therapeutics Market, Italy, Forecast ($m), 2011-2019 26Figure 19: Ankylosing Spondylitis Therapeutics Market, Spain, Revenue ($m), 2006-2011 27Figure 20: Ankylosing Spondylitis Therapeutics Market, Spain, Forecast ($m), 2011-2019 28Figure 21: Ankylosing Spondylitis Therapeutics Market, The UK, Revenue ($m), 2006-2011 29Figure 22: Ankylosing Spondylitis Therapeutics Market, The UK, Forecast ($m), 2011-2019 30Figure 23: Ankylosing Spondylitis Therapeutics Market, Japan, Revenue ($m), 2006-2011 31Figure 24: Ankylosing Spondylitis Therapeutics Market, Japan, Forecast ($m), 2011-2019 32Figure 25: Opportunity and Unmet Need in the Ankylosing Spondylitis Therapeutics Market, 2011 34Figure 26: Ankylosing Spondylitis Therapeutics, Strategic Competitor Assessment, 2011 36Figure 27: Ankylosing Spondylitis Therapeutics - Pipeline by Phase of Development, 2011 46Figure 28: Ankylosing Spondylitis Therapeutics, Pipeline by Mechanism of Action (%), 2011 48Figure 29: Ankylosing Spondylitis Therapeutics, Technology Trends Analytics Framework, 2011 49Figure 30: Ankylosing Spondylitis Therapeutics, Technology Trends Analytics Framework, Description, 2011 50Figure 31: Ankylosing Spondylitis Therapeutics, Clinical Trials by Country, 2011 52Figure 32: Ankylosing Spondylitis Therapeutics, Clinical Trials by Phase (%), 2011 53Figure 33: Ankylosing Spondylitis Therapeutics, Clinical Trials by Status of Development (%), 2011 54Figure 34: Ankylosing Spondylitis Therapeutics, Overall Sponsors (%), 2011 55Figure 35: Ankylosing Spondylitis Therapeutics, Prominent Sponsors (%), 2011 56Figure 36: Ankylosing Spondylitis Therapeutics, Top Companies Participating in Clinical Trials, 2011 57Figure 37: Ankylosing Spondylitis Therapeutics Market, Drivers and Restraints, 2011 58Figure 38: Implications for Future Market Competition in the Ankylosing Spondylitis Market, 2011 59Figure 39: Ankylosing Spondylitis Therapeutics Market, Pipeline by Company, 2011 60Figure 40: GlobalData Market Forecasting Model 69

Companies mentioned

NovartisUCB

More  Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker